Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Non-Current AssetsPayablesPreferred SharesPreferred Stock LiabilitiesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Crescent Biopharma (CBIO) Total Non-Current Liabilities (2016 - 2024)

Crescent Biopharma (CBIO) has disclosed Total Non-Current Liabilities for 8 consecutive years, with $4.3 million as the latest value for Q3 2024.

  • On a quarterly basis, Total Non-Current Liabilities fell 35.04% to $4.3 million in Q3 2024 year-over-year; TTM through Sep 2024 was $4.3 million, a 35.04% decrease, with the full-year FY2023 number at $6.9 million, down 22.28% from a year prior.
  • Total Non-Current Liabilities was $4.3 million for Q3 2024 at Crescent Biopharma, down from $4.4 million in the prior quarter.
  • In the past five years, Total Non-Current Liabilities ranged from a high of $14.6 million in Q4 2020 to a low of $4.3 million in Q3 2024.
  • A 5-year average of $9.5 million and a median of $9.3 million in 2022 define the central range for Total Non-Current Liabilities.
  • Peak YoY movement for Total Non-Current Liabilities: grew 7.28% in 2022, then tumbled 49.83% in 2023.
  • Crescent Biopharma's Total Non-Current Liabilities stood at $14.6 million in 2020, then dropped by 12.8% to $12.7 million in 2021, then plummeted by 30.31% to $8.9 million in 2022, then decreased by 22.28% to $6.9 million in 2023, then tumbled by 37.38% to $4.3 million in 2024.
  • Per Business Quant, the three most recent readings for CBIO's Total Non-Current Liabilities are $4.3 million (Q3 2024), $4.4 million (Q2 2024), and $5.3 million (Q1 2024).